X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs MYLAN (US) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   MYLAN
EQUITY SHARE DATA
    CIPLA
Mar-17
MYLAN
Dec-14
CIPLA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs6223,806-   
Low Rs4582,682-   
Sales per share (Unadj.) Rs181.91,303.0-  
Earnings per share (Unadj.) Rs12.9157.0-  
Cash flow per share (Unadj.) Rs29.3252.7-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs155.7647.7-  
Shares outstanding (eoy) m804.51378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x3.02.5 119.3%   
Avg P/E ratio x42.020.7 203.0%  
P/CF ratio (eoy) x18.412.8 143.5%  
Price / Book Value ratio x3.55.0 69.3%  
Dividend payout %15.50-   
Avg Mkt Cap Rs m434,5161,227,466 35.4%   
No. of employees `00023.025.0 92.2%   
Total wages/salary Rs m26,3380-   
Avg. sales/employee Rs Th6,349.119,720.0 32.2%   
Avg. wages/employee Rs Th1,143.00-   
Avg. net profit/employee Rs Th449.32,375.6 18.9%   
INCOME DATA
Net Sales Rs m146,302492,999 29.7%  
Other income Rs m2,287-2,874 -79.6%   
Total revenues Rs m148,589490,126 30.3%   
Gross profit Rs m24,758122,611 20.2%  
Depreciation Rs m13,22936,209 36.5%   
Interest Rs m1,59421,265 7.5%   
Profit before tax Rs m12,22262,264 19.6%   
Minority Interest Rs m0-255 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7982,618 68.7%   
Profit after tax Rs m10,35459,390 17.4%  
Gross profit margin %16.924.9 68.0%  
Effective tax rate %14.74.2 349.8%   
Net profit margin %7.112.0 58.7%  
BALANCE SHEET DATA
Current assets Rs m87,370433,411 20.2%   
Current liabilities Rs m33,081338,841 9.8%   
Net working cap to sales %37.119.2 193.4%  
Current ratio x2.61.3 206.5%  
Inventory Days Days8778 111.4%  
Debtors Days Days62107 58.1%  
Net fixed assets Rs m111,567114,054 97.8%   
Share capital Rs m1,60917,434 9.2%   
"Free" reserves Rs m123,6450-   
Net worth Rs m125,254245,069 51.1%   
Long term debt Rs m36,454366,109 10.0%   
Total assets Rs m209,532987,116 21.2%  
Interest coverage x8.73.9 220.7%   
Debt to equity ratio x0.31.5 19.5%  
Sales to assets ratio x0.70.5 139.8%   
Return on assets %5.78.2 69.8%  
Return on equity %8.324.2 34.1%  
Return on capital %8.513.6 62.4%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Net fx Rs m33,3880-   
CASH FLOW
From Operations Rs m23,82464,805 36.8%  
From Investments Rs m-13,127-51,107 25.7%  
From Financial Activity Rs m-13,239-17,076 77.5%  
Net Cashflow Rs m-2,478-3,378 73.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.86 Rs / USD

Compare CIPLA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare CIPLA With: TORRENT PHARMA  PANACEA BIOTECH  JUBILANT LIFE SCIENCES  SHASUN PHARMA  WOCKHARDT LTD.  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views On News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 18, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS